Announced
Synopsis
Recipharm, a contract development and manufacturing organization, agreed to acquire Arranta Bio, a biotechnology company, from Ampersand Capital Partners, a private equity firm. Financial terms were not disclosed. “We welcome Arranta and its team of experts who boast a strong reputation in the CDMO industry. This acquisition is another important step for us in growing our biologics business and developing a strong presence into the US. We look forward to working closely with the Arranta team, building links across the wider Recipharm organisation to make this business a huge success," Marc Funk, Recipharm CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.